Roka Bioscience (ROKA) 10-Q 10 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 07, 2014
Document And Entity Information [Abstract]	'	'
Document type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ROKA	'
Entity Registrant Name	'ROKA BIOSCIENCE, INC.	'
Entity Central Index Key	'0001472343	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,660,432

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets:	'	'
Cash and cash equivalents	$62,849	$32,728
Trade accounts receivable, net of $0 allowance for doubtful accounts	765	277
Inventories	4,894	3,879
Deferred tax assets	0	3,135
Prepaid expenses and other current assets	1,652	2,437
Total current assets	70,160	42,456
Property and equipment, net	12,688	14,510
Intangible assets, net	27,100	1,344
Goodwill	360	360
Other assets	317	444
Total assets	110,625	59,114
Current Liabilities:	'	'
Accounts payable	868	1,226
Short-term deferred payments	609	339
Notes payable, current	9,875	4,919
Accrued expenses	2,320	2,381
Total current liabilities	13,672	8,865
Deferred payments	10,314	3,205
Convertible preferred stock warrant liability	0	212
Deferred tax liabilities	40	40
Other long-term liabilities	338	339
Total liabilities	24,364	12,661
Commitments and Contingencies (See Note 9)	'	'
Stockholders’ Equity (Deficit):	'	'
Convertible preferred stock, value	0	0
Common stock, $0.001 par value: 500,000,000 shares of Common Stock authorized and 17,660,432 shares issued and outstanding at September 30, 2014; 141,963,421 shares of Series A common stock authorized and 1,181,936 shares issued and outstanding at December 31, 2013; and 292,414 shares of Series B common stock authorized and 3,129 shares issued and outstanding at December 31, 2013	18	8
Additional paid-in capital	211,816	19,422
Accumulated deficit	-125,573	-100,774
Total liabilities and stockholders’ equity (deficit)	86,261	-81,344
Total liabilities and stockholders' deficit	110,625	59,114
Series B convertible preferred stock, $0.001 par value: zero and 39,680,000 shares authorized; zero and 37,200,000 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively. (Liquidation Value: $37,200 at December 31, 2013) [Member]	'	'
Stockholders’ Equity (Deficit):	'	'
Convertible preferred stock, value	0	33,450
Series C convertible preferred stock, $0.001 par value: zero and 12,090,672 shares authorized, issued and outstanding at September 30, 2014 and December 31, 2013, respectively, (Liquidation Value: $16,020 at December 31, 2013) [Member]	'	'
Stockholders’ Equity (Deficit):	'	'
Convertible preferred stock, value	0	15,836
Series D convertible preferred stock, $0.001 par value: zero and 32,511,979 shares authorized, issued and outstanding at September 30, 2014 and December 31, 2013, respectively. (Liquidation Value $47,500 at December 31, 2013) [Member]	'	'
Stockholders’ Equity (Deficit):	'	'
Convertible preferred stock, value	0	43,272
Series E convertible preferred stock, $0.001 par value: zero and 33,601,367 shares authorized, zero and 32,934,700 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively. (Liquidation Value $41,992 at December 31, 2013) [Member]	'	'
Stockholders’ Equity (Deficit):	'	'
Convertible preferred stock, value	$0	$35,239

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$0	$0
Convertible preferred stock, shares outstanding (in shares)	0	'
Common stock par value (in USD per share)	$0.00	$0.00
Common stock, shares authorized (in shares)	500,000,000	'
Series B Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in USD per share)	$0	$0.00
Convertible preferred stock, shares authorized (in shares)	0	39,680,000
Convertible preferred stock, shares issued (in shares)	0	37,200,000
Convertible preferred stock, shares outstanding (in shares)	0	37,200,000
Convertible preferred stock, liquidation value	0	37,200
Series C Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in USD per share)	$0	$0.00
Convertible preferred stock, shares authorized (in shares)	0	12,090,672
Convertible preferred stock, shares issued (in shares)	0	12,090,672
Convertible preferred stock, shares outstanding (in shares)	0	12,090,672
Convertible preferred stock, liquidation value	0	16,020
Series D Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in USD per share)	$0	$0.00
Convertible preferred stock, shares authorized (in shares)	0	32,511,979
Convertible preferred stock, shares issued (in shares)	0	32,511,979
Convertible preferred stock, shares outstanding (in shares)	0	32,511,979
Convertible preferred stock, liquidation value	0	47,500
Series E Convertible Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in USD per share)	$0	$0.00
Convertible preferred stock, shares authorized (in shares)	0	33,601,367
Convertible preferred stock, shares issued (in shares)	0	32,934,700
Convertible preferred stock, shares outstanding (in shares)	0	32,934,700
Convertible preferred stock, liquidation value	$0	$41,992
Preferred Stock [Member]	'	'
Convertible preferred stock, par value (in USD per share)	$0.00	$0
Convertible preferred stock, shares authorized (in shares)	20,000,000	0
Convertible preferred stock, shares issued (in shares)	0	0
Convertible preferred stock, shares outstanding (in shares)	0	0
Common Stock [Member]	'	'
Common stock, shares authorized (in shares)	500,000,000	0
Common Stock, shares issued (in shares)	17,660,432	0
Common Stock, shares outstanding (in shares)	17,660,432	0
Series A Common Stock [Member]	'	'
Common stock, shares authorized (in shares)	0	141,963,421
Common Stock, shares issued (in shares)	0	1,181,936
Common Stock, shares outstanding (in shares)	0	1,181,936
Series B Common Stock [Member]	'	'
Common stock, shares authorized (in shares)	0	292,414
Common Stock, shares issued (in shares)	0	3,129
Common Stock, shares outstanding (in shares)	0	3,129

Condensed_Statements_of_Operat

Condensed Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$1,483	$556	$3,701	$1,493
Operating expenses:	'	'	'	'
Cost of revenue	2,578	1,280	5,416	4,829
Research and development	1,922	2,139	5,991	5,836
Selling, general and administrative	4,618	4,363	14,214	12,896
Amortization of intangible assets	738	42	822	126
Total operating expenses	9,856	7,824	26,443	23,687
Loss from operations	-8,373	-7,268	-22,742	-22,194
Other income (expense):	'	'	'	'
Change in fair value of financial instruments	-223	-2,055	-785	-2,630
Interest income (expense), net	-476	-91	-1,244	-245
Loss before income taxes	-9,072	-9,414	-24,771	-25,069
Income tax provision (benefit)	11	35	28	36
Net loss and comprehensive loss	($9,083)	($9,449)	($24,799)	($25,105)
Net Loss per Common Share:	'	'	'	'
Basic and diluted (in USD per share)	($0.64)	($17)	($4.78)	($51.05)
Weighted average common shares outstanding used in computing net loss per common share:	'	'	'	'
Basic and diluted (in shares)	14,153,715	555,910	5,188,516	488,190

Condensed_Statement_of_Convert

Condensed Statement of Convertible Preferred Stock and Stockholders' Deficit (USD $)

Total

Preferred Stock [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Accumulated Deficit [Member]

IPO [Member]

IPO [Member]

IPO [Member]

Royalty Reduction [Member]

Royalty Reduction [Member]

Royalty Reduction [Member]

Series E Convertible Preferred Stock [Member]

Series A Preferred Stock [Member]

In Thousands, except Share data

Common Stock [Member]

Additional Paid-in Capital [Member]

Common Stock [Member]

Additional Paid-in Capital [Member]

Preferred Stock [Member]

Preferred Stock [Member]

Beginning Balance at Dec. 31, 2012

($69,728)

$100,537

$8

$1,460

($71,196)

'

'

'

'

'

'

'

'

Beginning Balance (in shares) at Dec. 31, 2012

'

84,927,615

683,428

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

32,934,700

'

Issuance of stock

'

'

'

'

'

'

'

'

'

'

'

35,094

'

Conversion of convertible preferred stock into Common Stock (in shares)

'

-3,296,082

53,688

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock into Common Stock

17,206

-17,206

'

17,206

'

'

'

'

'

'

'

'

'

Issuance of restricted shares to employees (in shares)

'

'

439,300

'

'

'

'

'

'

'

'

'

'

Exercise of options for Common Stock (in shares)

'

'

8,649

'

'

'

'

'

'

'

'

'

'

Exercise of options for Common Stock

20

'

'

20

'

'

'

'

'

'

'

'

'

Exercise of warrants for Series A Preferred Stock (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

171,118

Exercise of warrants for Series A Preferred Stock

'

'

'

'

'

'

'

'

'

'

'

'

9,412

Stock-based compensation expense

696

'

'

696

'

'

'

'

'

'

'

'

'

Deemed dividends

40

-40

'

40

'

'

'

'

'

'

'

'

'

Net loss

-29,578

'

'

'

-29,578

'

'

'

'

'

'

'

'

Ending Balance at Dec. 31, 2013

-81,344

127,797

8

19,422

-100,774

'

'

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2013

'

114,737,351

1,185,065

'

'

'

'

'

'

'

'

'

'

Series E convertible preferred stock issuance costs

'

-99

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock (in shares)

'

'

'

'

'

'

5,000,000

'

'

'

'

'

'

Issuance of stock

'

'

'

'

'

53,215

5

53,210

'

'

'

'

'

Conversion of convertible preferred stock into Common Stock (in shares)

'

-114,737,351

10,494,557

'

'

'

'

'

'

'

'

'

'

Conversion of convertible preferred stock into Common Stock

127,698

-127,698

4

127,694

'

'

'

'

'

'

'

'

'

Reclassification of warrants to purchase redeemable convertible preferred stock into warrants to purchase Common Stock

1,364

'

'

1,364

'

'

'

'

'

'

'

'

'

Issuance of common stock for royalty reduction (in shares)

'

'

'

'

'

'

'

'

'

865,063

'

'

'

Issuance of common stock for royalty reduction

'

'

'

'

'

'

'

'

9,092

1

9,091

'

'

Exercise of options for Common Stock (in shares)

'

'

115,747

'

'

'

'

'

'

'

'

'

'

Exercise of options for Common Stock

270

'

'

270

'

'

'

'

'

'

'

'

'

Stock-based compensation expense

765

'

'

765

'

'

'

'

'

'

'

'

'

Net loss

-24,799

'

'

'

-24,799

'

'

'

'

'

'

'

'

Ending Balance at Sep. 30, 2014

$86,261

$0

$18

$211,816

($125,573)

'

'

'

'

'

'

'

'

Ending Balance (in shares) at Sep. 30, 2014

'

0

17,660,432

'

'

'

'

'

'

'

'

'

'

Condensed_Statement_of_Convert1

Condensed Statement of Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) (USD $)	Dec. 31, 2013
	Preferred Stock [Member]
Issuance of Series E convertible preferred stock for cash (in USD per share)	$1.27

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities	'	'
Net loss	($24,799)	($25,105)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	2,690	1,897
Change in fair value of financial instruments	785	2,630
Loss on disposal of property and equipment	98	0
Provisions for inventory	991	509
Share-based compensation expense	765	530
Non-cash interest expense	800	266
Changes in operating assets and liabilities:	'	'
Accounts receivable	-549	-211
Inventories	-2,005	-229
Prepaid expenses and other assets	492	-129
Accounts payable and accrued expenses	-397	-1,745
Deferred taxes	3,135	0
Other liabilities	-2	20
Net cash used in operating activities	-17,996	-21,567
Cash flows from investing activities	'	'
Purchases of property and equipment, net of sales	-139	-2,892
Royalty buy-down	-10,500	0
Net cash used in investing activities	-10,639	-2,892
Cash flows from financing activities	'	'
Net proceeds from issuance of convertible preferred stock and warrants	-99	24,919
Net proceeds from issuance of debt and warrants	5,000	0
Net proceeds from warrant exercises	0	171
Proceeds from exercise of stock options	270	19
Proceeds from issuance of common stock, net of issuance costs	53,585	0
Net cash provided by financing activities	58,756	25,109
Net change in cash and cash equivalents	30,121	650
Cash and cash equivalents, beginning of period	32,728	17,314
Cash and cash equivalents, end of period	$62,849	$17,964

Business_Overview

Business Overview	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Business Overview	'
	BUSINESS OVERVIEW
	Business
	Roka Bioscience, Inc. (“Roka” or “the Company”) is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens. The Company was established in September 2009 through the acquisition of industrial testing assets and technology from Gen-Probe Incorporated, which was subsequently acquired by Hologic, Inc. (herein referred to as “Gen-Probe”).
	The Company has limited capital resources and has experienced negative cash flows from operations and has incurred net losses since inception. The Company expects to continue to experience negative cash flows from operations and incur net losses in the near term as it devotes substantially all of its efforts on commercial product launch and continued product development. The Company’s business is subject to significant risks and its ability to successfully develop, manufacture and commercialize proprietary products is dependent upon many factors including, but not limited to, risks and uncertainties associated with the supply of molecular diagnostic instruments (“Atlas instruments”) and materials, product development, manufacturing scale-up, attracting and retaining key personnel, customer acceptance as well as competition.
	On July 22, 2014, the Company closed an initial public offering ("IPO") in which 5,000,000 shares of common stock were sold at $12.00 per share, before underwriting discounts. The Company received $53.2 million of net proceeds from the offering after deducting underwriting discounts, commissions and offering expenses. In connection with the closing of the IPO, all shares of the Company’s Class A common stock (“Common A”) and Class B common stock (“Common B”) were converted into a new class of common stock ("Common Stock") on a 1:1basis and all shares of Series B Convertible Preferred Stock (“Series B”), Series C Convertible Preferred Stock (“Series C”), Series D Convertible Preferred Stock (“Series D”) and Series E Convertible Preferred Stock (“Series E”) collectively referred to as “Convertible Preferred Stock” were converted into the new class of common stock at their respective conversion ratios. Additionally, in conjunction with the completion of the IPO, the Company chose to exercise its royalty reduction option pursuant to the amended license agreement with Gen-Probe. See Note 6 for further details.
	The Company may need to raise additional capital through the sale of equity and/or debt securities in the future. There is no assurance that the Company will be able to raise needed capital under acceptable terms, if at all. The sale of additional equity may dilute existing shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding preferred and common stock. Issued debt securities may contain covenants and limit the Company’s ability to pay dividends or make other distributions to stockholders. In addition, the Company’s debt agreements contain material adverse change clauses which allows the lenders to call the debt based on subjective factors regarding the Company’s business and performance which may be considered a material adverse change.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying unaudited condensed financial statements of Roka Bioscience, Inc. have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto prepared in accordance with U.S. GAAP. The unaudited financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited financial statements for the year ended December 31, 2013. The condensed Balance Sheet as of December 31, 2013 was derived from the Company’s audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. There have been no changes to the Company’s significant accounting policies since December 31, 2013. The unaudited financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”) on July 16, 2014 (the “Prospectus”).
	Prior Period Adjustments
	Previously, the Company calculated the fair value of its convertible preferred stock warrants outstanding using a time period based upon an estimated liquidation date. During the three months ended March 31, 2014, it was determined that a liquidation date cannot be reasonably estimated, nor do these warrants automatically expire upon a liquidation event such as an initial public offering, and consequently the life used to value these warrants should reflect the expiration date of each warrant. As a result of this change in estimate, during the three months ended March 31, 2014 the Company recognized the following prior period expenses: approximately $435,000 related to the change in fair value of warrants, approximately $26,000 of interest expense and approximately $77,000 of other expenses as a result of the change in calculation of the fair value of warrants. Additionally, this change in valuation resulted in a reduction of notes payable of approximately $77,000, deemed to be an additional debt discount which will be accreted to notes payable over the life of the loan with a corresponding charge to interest expense. Furthermore, the change in valuation resulted in an increase in deferred financing costs of $77,000 which was expensed in the nine months ended September 30, 2014. Management does not believe these adjustments are material to the current or prior periods.
	Common A and Common B Reverse Stock Split
	In July 2014, the Company’s board of directors authorized and the Company’s shareholders approved an 11.04:1 reverse stock split of the Company’s Common A and Common B shares, effective on July 3, 2014. In addition, effective on the date of the reverse stock split, the conversion ratio of Convertible Preferred Stock was adjusted by a factor of 11.04 and consequently, each share of Series B, Series C and Series E became convertible into approximately 0.0906 shares of Common Stock and each share of Series D became convertible into approximately 0.0937 shares of Common Stock. As stated in Note 1, all shares of Convertible Preferred Stock converted into Common Stock upon the completion of the Company's IPO. The Company’s historical share and per share information have been retroactively adjusted to give effect to this reverse split and corresponding change in conversion ratio.
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, and early adoption is permitted. The Company is currently in the process of evaluating the impact this new guidance will have.
	In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-9, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-9 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact this new guidance will have.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2014
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents	'
	CASH AND CASH EQUIVALENTS
	The Company’s entire balance of cash and cash equivalents as of September 30, 2014 was held in demand accounts with one financial institution, which potentially subjects the Company to significant concentrations of credit risk.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventories	'
	INVENTORIES
	The following table provides details of the Company’s net inventories (amounts in thousands):
		As of September 30,		As of December 31,
		2014		2013
	Raw materials	$	1,597	$	1,846
	Work in process	—		—
	Finished goods	3,297		2,033
		$	4,894	$	3,879

Property_and_Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property and Equipment	'
	PROPERTY AND EQUIPMENT
	The following table provides details of the Company’s property and equipment (amounts in thousands):
		As of September 30,			As of December 31,
		2014			2013
	Atlas instruments	$	10,160		$	10,330
	Manufacturing equipment	2,801			2,801
	Laboratory equipment	2,967			2,923
	Computer and office equipment	1,435			1,388
	Leasehold improvements	1,318			1,272
	Software	1,113			1,106
	Total property and equipment	$	19,794		$	19,820
	Less: Accumulated depreciation	(7,106		)	(5,310		)
	Total	$	12,688		$	14,510
	Atlas instruments include instruments intended for placement with customers and instruments placed with customers under lease agreements. As of September 30, 2014 and December 31, 2013, the cost of Atlas instruments, which represents equipment on lease or held for lease, was $9.1 million and $9.8 million, respectively, net of accumulated depreciation of $1.1 million and $0.5 million, respectively.
	Expenses for depreciation of property and equipment were incurred as follows (amounts in thousands):
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2014			2013			2014		2013
	Depreciation expense	$	623		$	582		$	1,867	$	1,677

Intangible_Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets	'
	INTANGIBLE ASSETS
	In June 2014, the Company entered into an amendment to its license agreement with Gen-Probe. Under the amendment, the Company obtained a two-year option to reduce the royalty rate it pays to Gen-Probe in exchange for an option payment of $2.5 million. Upon completion of its IPO in July 2014, the Company exercised its option and issued to Gen-Probe 865,063 shares of common stock at $10.51 per share and made a cash payment of $8.0 million. The Company is required to make additional cash payments of $5.0 million on January 1, 2018 and $5.0 million on January 1, 2020.
	The aggregate cash and stock payments made to Gen-Probe along with the present value of the two $5.0 million payments described above were recorded as a $26.6 million addition to the Company's intangible technology asset in Intangible assets on the Balance Sheet and will be amortized through December 31, 2021, the end of the estimated remaining life of the technology asset. See Note 8 for further details on the additional required future cash payments described above.
	Pursuant to the terms of the license agreement amendment, the Company committed to additional future contingent payments, as described in Note 10 below. Such additional payments will further reduce the royalty rate the Company pays to Gen-Probe, will also be recorded as additions to the Company's intangible technology asset upon payment and amortized over the estimated remaining life of the technology asset.

Accrued_Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Accrued Expenses	'
	ACCRUED EXPENSES
	The following table provides details of the Company’s accrued expenses (amounts in thousands):
		As of September 30,		As of December 31,
		2014		2013
	Employee related	$	1,145	$	888
	Professional services	740		1,328
	Other	435		165
	Total accrued expenses	$	2,320	$	2,381
	Included within Professional services and Other as of December 31, 2013, in the above table is approximately $526,000 for issuance costs related to our IPO.

Deferred_Payments

Deferred Payments	9 Months Ended
	Sep. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Deferred Payments	'
	DEFERRED PAYMENTS
	Gen-Probe supply agreement
	In May 2011, the Company entered into a supply agreement with Gen-Probe to purchase Atlas instruments. Pursuant to the terms of the agreement, the Company can defer up to one half of the purchase price for up to 54 months from the date of delivery. The deferred amounts do not bear interest, and the Company has determined that ASC 835-30 Imputation of interest (“ASC-835”) applies. Accordingly, the Company recorded the imputed interest component as a reduction of the deferred payment and as a reduction of the asset cost. The supply agreement provides for variable repayment terms based on a percentage of net sales as defined in the agreement, and the Company has estimated its net sales in determining amounts due for the 54 month term. The following table summarizes the amounts deferred under this agreement (amounts in thousands):
		As of September 30,			As of December 31,
		2014			2013
	Current
	Deferred payments, gross	$	1,002		$	759
	Imputed interest	(393		)	(420		)
	Deferred payments, net	$	609		$	339
	Long-term
	Deferred payments, gross	$	3,776		$	4,053
	Imputed interest	(557		)	(848		)
	Deferred payments, net	$	3,219		$	3,205
	The Company estimated the interest rate implicit in the extended payment terms by considering the rate at which it could obtain financing of a similar nature from other sources at the date of the transaction, as well as prevailing rates for similar debt instruments of issuers with similar credit ratings, the estimated effective interest rate used, ranges from 9.9% to 11.2%.
	In the three and nine months ended September 30, 2014, the Company recorded approximately $104,000 and $318,000, respectively, and in the three and nine months ended September 30, 2013, the Company recorded approximately $102,000 and $266,000, respectively, as non-cash interest expense related to the deferred payments pursuant to the supply agreement with Gen-Probe.
	Gen-Probe license amendment
	The amendment to the license agreement with Gen-Probe detailed in Note 6 includes a $5.0 million payment due on January 1, 2018 and a $5.0 million payment due on January 1, 2020. The amendment does not require any interest payments or state an interest rate and as such, the Company has determined that imputed interest must be calculated and recognized in accordance with ASC-835. As such, the payments are recorded in Deferred payments on the Balance Sheet at their present values based upon a 7.6% interest rate for the payment due on January 1, 2018 and a 9.0% interest rate for the payment due on January 1, 2020. The difference between the present value and the amount payable will be accreted to Deferred payments over the respective term with a corresponding charge to Interest expense.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Notes Payable	'
	NOTES PAYABLE
	In November 2013, the Company entered into two loan and security agreements, under which the Company may borrow up to an aggregate of $15.0 million in three separate $5.0 million tranches upon meeting certain provisions. The first tranche is subject to the terms and conditions of the loan and security agreement entered into with Comerica Bank (“Comerica”) and the second and third tranches are subject to the terms and conditions of the loan and security agreement entered into with TriplePoint Capital LLC (“TriplePoint”).
	The loan and security agreement with Comerica (the “Comerica Loan”), provided for borrowing of up to $5.0 million and accrues interest at Comerica’s Prime Referenced Rate (as defined in the loan agreement with Comerica), subject to a floor of the daily adjusting LIBOR rate plus 2.5%, plus 3.15%. As of September 30, 2014, the rate was 6.4%. The loan is interest-only until June 1, 2015 and matures in 42 months. After the 18-month interest-only period, the Company will make 23 consecutive monthly payments which will consist of accrued interest and equal principal payments in accordance with a 30-month amortization schedule. On the 24th month following the interest only period, the Company will make a lump sum payment for the remaining outstanding principal and interest due. Upon the closing of the loan and security agreements, the Company borrowed $5.0 million from Comerica.
	The loan and security agreement with TriplePoint (the “TriplePoint Loan”), provided for borrowings of up to $10.0 million. The TriplePoint loan provided that the Company may borrow up to $5.0 million in the second tranche, consisting of one or more term loan advances, before March 31, 2014 and if the Company had generated at least $10.0 million in revenue between November 21, 2013 and September 30, 2014, it would be eligible to borrow up to an additional $5.0 million in the third tranche. The Company did not meet the revenue requirement described above in order to borrow funds under the third tranche. In March 2014, the Company borrowed $5.0 million from TriplePoint under the second tranche, such borrowings will accrue interest at a rate of 9.5%. The TriplePoint Loan is repayable over 36 months from the borrowing date with an interest-only period of 12 months and equal monthly installments of principal and interest over the remaining term of the loan after the interest-only period.
	The loan agreements do not contain any financial covenants. However, the agreements contain various covenants that limit the Company’s ability to engage in specified types of transactions, including limiting the Company’s ability to; sell, transfer, lease or dispose of certain assets; engage in certain mergers and consolidations; incur debt or encumber or permit liens on certain assets, make certain restricted payments, including paying dividends on, or repurchasing or making distributions with respect to, the Company’s Common Stock; and enter into certain transactions with affiliates. Additionally, the Company has pledged substantially all of its assets except intellectual property as collateral for the loans.
	In connection with the closing of the loan and security agreements, the Company issued warrants to Comerica and TriplePoint to purchase up to an aggregate of 352,941 shares of Series E with an exercise price of $1.28. Upon the completion of the IPO, such warrants became exercisable for 31,968 shares of Common Stock with an exercise price of $14.08.
	In connection with the Comerica Loan, the Company recorded the liability for the note as $4.9 million, net of expenses paid to Comerica and the value of the warrant issued to Comerica. The difference between the liability recorded and the face value of the note will be accreted to Notes payable over the term of the loan with a corresponding charge to interest expense. Additionally, the Company incurred debt issuance costs of approximately $76,000 which were capitalized within Other assets on the Balance Sheet and will be amortized to Interest expense over the life of the loan using the interest method.
	In connection with the closing of the TriplePoint Loan, the Company incurred approximately $153,000 of debt issuance costs which were capitalized with Other assets on the Balance Sheet and will be amortized to Interest expense over the term the funds are available to Roka to be borrowed.
	In connection with the borrowings under the second tranche, the TriplePoint warrants became exercisable for an additional 156,863 shares of Series E. Upon the completion of the IPO, such warrants became exercisable for 14,209 shares of Common Stock with an exercise price of $14.08. Furthermore, the Company recorded the liability for the note as $5.0 million less the value of the associated warrant of approximately $135,000. The difference between the liability recorded and the face value of the note will be accreted to Notes payable over the term of the loan with a corresponding charge to Interest expense.
	As of September 30, 2014, approximately $1.8 million is classified as Notes payable, current on the Balance Sheet as it is due within one year from the Balance Sheet date. The remaining $8.2 million has also been classified as Notes payable, current due to a material adverse change clause within the loan agreements which allow Comerica and TriplePoint to call the debt based on subjective factors regarding the Company’s business and performance.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	COMMITMENTS AND CONTINGENCIES
	Operating leases
	The Company has not entered into any new operating leases or amended any operating leases during the nine months ended September 30, 2014.
	Contractual obligations
	During the nine months ended September 30, 2014, there have been no significant changes to the Company’s contractual obligations as disclosed in the Company’s most recent audited financial statements except as described below.
	The amendment to the license agreement with Gen-Probe detailed in Note 6 provides for additional milestone payments of up to $6.0 million to further reduce the royalty rate. Such payments are required to be made upon meeting certain revenue milestones or may be made at the election of the Company prior to meeting the revenue milestones.
	Legal Matters
	The Company may periodically become subject to legal proceedings and claims arising in connection with its business. The Company is not currently involved in any legal proceedings nor are there any claims against the Company pending.
	The Company sells its products in various jurisdictions and is subject to federal, state and local taxes including, where applicable, sales and use tax. While the Company believes that it has properly paid or accrued for all such taxes based on its interpretation of applicable law, tax laws are complex and interpretations differ. Periodically, the Company may be audited by taxing authorities, and it is possible that additional assessments may be made in the future.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	FAIR VALUE MEASUREMENTS
	The Company’s financial instruments consist of cash and cash equivalents, trade accounts receivable, accounts payable, short-term deferred payments, deferred payments, notes payable, accrued expenses and Convertible Preferred Stock Warrants. The carrying amounts of cash and cash equivalents, trade accounts receivable, accounts payable, short-term deferred payments and accrued expenses approximate their fair values because of the short-term nature of the instruments, or, in the case of the deferred payments and notes payable, because the interest rates the Company believes it could obtain for similar borrowings is similar to its existing interest rates.  In conjunction with the closing of the Company’s IPO, the warrants exercisable for shares of its Series B and Series E Preferred Stock were automatically converted into warrants exercisable for shares of its Common Stock, resulting in the reclassification of the related convertible preferred stock warrant liability to additional paid-in capital as the warrants to purchase shares of common stock met the criteria for equity classification. The warrant liability was re-measured to fair value prior to reclassification to additional paid-in capital.
	The following table summarizes the fair value information for the Company’s cash held in money market deposit accounts and its Convertible Preferred Stock Warrants at September 30, 2014 and December 31, 2013 (amounts in thousands):
					Fair value measurements using:
		Carrying			Quoted Prices in			Significant Other	Significant
		Value			Active Markets			Observable Inputs	Unobservable
					(Level 1)			(Level 2)	Inputs (Level 3)
	As of September 30, 2014
	Financial Assets:
	Money market deposit accounts	$	62,538		$	62,538		—	—
	As of December 31, 2013
	Financial Assets:
	Money market deposit accounts	$	25,470		$	25,470		—	—
	Financial Liabilities:
	Convertible Preferred Stock Warrants	$	212		—			—	$	212
	Some of the Company’s cash and cash equivalents are held in money market deposit accounts which are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices or market prices for similar securities.
	Per ASC 820, Fair Value Measurements and Disclosures, (“ASC 820”) the Convertible Preferred Stock Warrants are classified within Level 3 of the fair value hierarchy as they are revalued to their fair value, using the Black-Scholes option-pricing model, at each reporting period end and any change in fair value is reflected in the Statement of Operations and Comprehensive Loss. There have been no transfers between levels during the reporting period.
	The table below provides a summary of the changes in the Convertible preferred stock warrant liability during the nine months ended September 30, 2014 and the nine months ended September 30, 2013 (amounts in thousands):
		For the Nine Months Ended September 30,
		2014			2013
	Balance at beginning of period	$	212		$	100
	Issuance of Series A Warrants	—			6,674
	Increase in Series E warrant shares	135			—
	Change in fair value of warrants(1)	1,017			2,630
	Settlement of Series A Warrants	—			(9,240		)
	Reclassification to equity(2)	(1,364		)	—
	Balance at end of period	$	—		$	164
	-1	Includes $666,000 of prior period fair value adjustments as discussed in Note 2 above.
	-2	The warrants were re-measured to fair value and reclassified to additional paid-in capital upon the initial public offering.

Convertible_Preferred_Stock_an

Convertible Preferred Stock and Stockholders' Equity (Deficit)	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
Convertible Preferred Stock and Stockholders' Equity (Deficit)	'
	CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
	Prior to the IPO, the Company had multiple classes of preferred stock for which shares were authorized, issued and outstanding. At the closing of the Company's IPO, all shares of Convertible Preferred Stock converted into 10,494,557 shares of Common Stock and as of September 30, 2014, there are zero shares of Convertible Preferred Stock outstanding.
	Registration rights
	Upon the expiration of a 180-day lock-up period that commenced on July 16, 2014, holders of at least 51% of Common Stock issued upon the conversion of Convertible Preferred Stock may require that the the Company file a registration statement under the Securities Act covering the registration of such shares of Common Stock issued upon the conversion of Convertible Preferred Stock into Common Stock. These rights are provided under the terms of an investor rights agreement between the Company and the holders of the Company’s Convertible Preferred Stock and Convertible Preferred Stock Warrants.
	Authorized stock
	In connection with the seventh amended and restated certificate of incorporation effective on July 22, 2014, the total authorized shares of stock was changed to 520,000,000 of which 500,000,000 shares shall be a class designated as common stock with a par value of $0.001 per share and 20,000,000 shares shall be a class designated as preferred stock with a par value of $0.001 per share.

StockBased_Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation	'
	STOCK-BASED COMPENSATION
	Under the Roka Bioscience, Inc. 2009 Equity Incentive Plan (the “2009 Plan”), as amended on June 13, 2013, incentive and non-qualified stock options and restricted stock may be granted for up to a maximum of 2,028,850 shares to employees, consultants and directors of the Company.
	Effective upon the closing of the IPO, the Company adopted the Roka Bioscience, Inc. 2014 Equity Incentive Plan (the "2014 Plan"). The 2014 Plan initially makes available 1,086,956 shares to be granted to employees, officers, directors, consultants, advisors or other individual service providers of the Company. The number of shares of Common Stock available for issuance under the 2014 Plan shall automatically increase on January 1st of each year for a period of ten years commencing on January 1, 2015 and ending on (and including) January 1, 2024, in an amount equal to 3% of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year.
	Stock options and shares of restricted stock granted under the 2009 Plan and the 2014 Plan have a maximum contractual term of ten years from the date of grant and generally vest over four years. For stock options, the exercise price may not be less than the fair value of the stock on the grant date.
	The Company recognized stock compensation expense as follows (amounts in thousands):
		For the Three Months Ended September 30,					For the Nine Months Ended September 30,
		2014			2013		2014		2013
	Stock options	$	41		$	56	$	174	$	170
	Restricted stock	$	200		$	120	$	591	$	360
	Under the 2009 Plan, the Company granted approximately 4,000 stock options and 105,000 stock options during the nine months ended September 30, 2014 and 2013, respectively, valued at approximately $18,000 and $104,000, respectively. There were no grants of options or restricted stock under the 2014 Plan during the nine months ended September 30, 2014.
	The Company determines the fair value of stock option awards at the date of grant using a Black-Scholes valuation model. This model requires the Company to make assumptions and judgments on the expected volatility, dividend yield, the risk-free interest rate and the expected term of the stock options. The following ranges of assumptions were utilized for stock options granted:
			For the Nine Months Ended September 30,
			2014	2013
	Expected life in years		5.9-6.0	5.7-6.0
	Interest rate		2.01%-2.04%	0.99%-1.94%
	Volatility		60%	70%
	Dividend yield		—	—
	The Company estimates the expected life of its employee stock options using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to its lack of sufficient historical data. The risk-free interest rates are based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The expected stock price volatility rates are based on average historical volatilities of the common stock of a group of public companies in similar industries. The Company has no history or expectations of paying dividends on its Common Stock and therefore uses a zero percent dividend yield in the Black-Scholes option pricing model.

Warrants

Warrants	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Warrants	'
	WARRANTS
	Immediately prior to the Company's IPO, the Company had Series B Warrants outstanding which allowed their holders to purchase 2,480,000 shares of Series B at an exercise price of $1.00 per share. In connection with the IPO, the warrants converted into warrants to purchase Common Stock at their conversion rate of approximately 0.0906 common warrant shares to one Series B warrant share. Such warrants expire in September 2016, whereupon any warrants that remain unexercised will be exercised automatically in whole in a cashless exercise resulting in an issuance, to the holders of the warrants, the number of shares with a value equal to the intrinsic value of the warrants at the time of expiry.
	In connection with the closing of the loan and security agreements discussed in Note 8, the Company issued warrants to Comerica and TriplePoint to purchase up to an aggregate of 352,941 shares of Series E with an exercise price of $1.28. Upon issuance, the Company recorded liabilities on the Balance Sheet of approximately $28,000 and $55,000 for the warrants issued to Comerica and TriplePoint, respectively. The initial fair value of the warrant issued to Comerica of approximately $28,000 was deemed a discount on the debt issued by Comerica and is being accreted to interest expense over the term of the Comerica Loan. The initial fair value of the warrants issued to TriplePoint of approximately $55,000 is included in the $153,000 of debt issuance costs which were capitalized in Other assets on the Balance Sheet and will be amortized to Interest expense. In connection with the borrowings made under the second tranche in March 2014, one of the TriplePoint warrants became exercisable for an additional 156,863 shares of Series E. The initial fair value of approximately $135,000 for the warrants issued to TriplePoint in connection with the borrowings under the second tranche was deemed a discount on the debt issued by TriplePoint and is being accreted to interest expense over the term of the second tranche. In connection with the IPO, the Series E warrants converted into warrants to purchase common stock at their conversion rate of approximately 0.0906 common warrant shares to one Series E warrant share.
	As of September 30, 2014, there were 270,813 warrant shares outstanding with a weighted average exercise price of $11.56 per share. See Note 10 for a summary of the changes in the Convertible preferred stock warrant liability for the nine months ended September 30, 2014 and 2013.

Net_Loss_Per_Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	NET LOSS PER SHARE
	Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average shares outstanding during the period, without consideration for common stock equivalents. The weighted-average common shares outstanding excludes unvested restricted stock which although such shares are legally issued and outstanding, are not required to share in losses of the Company and are therefore excluded from the net loss per share calculation. Diluted net loss per share is calculated by adjusting the weighted-average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the diluted net loss per share calculation, Convertible Preferred Stock, stock options and warrants are considered to be common stock equivalents but are excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive. Therefore, basic and diluted net loss per share applicable to common stockholders were the same for all periods presented. Previously, the Company had two classes of common stock outstanding. In connection with the IPO, the two classes were converted into a new class of Common Stock. The tables in this footnote are retroactively adjusted to show the results as if only the new class of Common Stock was outstanding for the entirety of each of the respective periods.
		For the Three Months Ended September 30,							For the Nine Months Ended September 30,
		2014				2013			2014			2013
	Net loss applicable to common shareholders (thousands)	$	(9,083	)		$	(9,449	)	$	(24,799	)	$	(25,105	)
	Deemed dividend (thousands)	—				—			—			184
	Net loss applicable to common shareholders for computing loss per share (thousands)	$	(9,083	)		$	(9,449	)	$	(24,799	)	$	(24,921	)
	Basic and diluted weighted average common shares outstanding	14,153,715				555,910			5,188,516			488,190
	Basic and diluted loss per share	$	(0.64	)		$	(17.00	)	$	(4.78	)	$	(51.05	)
	As the Company incurred a loss for the three and nine months ended September 30, 2014 and 2013, all unvested restricted stock awards were excluded from the calculation of basic net loss per share and all potential Common Stock shares issuable for Convertible Preferred Stock, stock options and warrants were excluded from the calculation of diluted net loss per share, as the effect of including them would have been anti-dilutive. Had the Company not incurred a loss, the dilutive effect of the unvested restricted stock awards on basic weighted average common shares outstanding and the dilutive effect of potential Common Stock shares issuable for Convertible Preferred Stock, stock options and warrants on the weighted-average number of Common Stock shares outstanding would have been as follows:
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2014			2013			2014		2013
	Basic weighted average shares outstanding	14,153,715			555,910			5,188,516		488,190
	Dilutive effect of unvested restricted stock	301,846			47,278			262,861		21,724
	Basic weighted average shares outstanding had the Company not incurred a loss	14,455,561			603,188			5,451,377		509,914
	Dilutive effect of Convertible Preferred Stock	1,939,212			8,972,373			7,642,775		8,198,836
	Dilutive effect of warrants	208			—			69		—
	Dilutive effect of stock options	339,272			192,005			363,792		96,197
	Diluted weighted average shares outstanding had the Company not incurred a loss	16,734,253			9,767,566			13,458,013		8,804,947

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	SEGMENT INFORMATION
	The Company operates in a single reportable segment. During the nine months ended September 30, 2014, the Company had four customers which each generated more than 10% of the Company’s revenues. These four customers accounted for revenues of approximately $1.1 million, $648,000, $631,000 and $411,000, respectively. During the nine months ended September 30, 2013, the Company had two customers which each generated more than 10% of the Company’s revenues. These two customers accounted for revenues of approximately $504,000 and $457,000, respectively.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	SUBSEQUENT EVENTS
	The Company has evaluated subsequent events through the date of this filing and notes no events requiring disclosure.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed financial statements of Roka Bioscience, Inc. have been prepared by the Company in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting, which do not conform in all respects to the requirements of U.S. GAAP for annual financial statements. Accordingly, these condensed notes to the unaudited financial statements should be read in conjunction with the 2013 audited financial statements and notes thereto prepared in accordance with U.S. GAAP. The unaudited financial statements have been prepared using accounting policies that are consistent with the policies used in preparing the Company’s audited financial statements for the year ended December 31, 2013. The condensed Balance Sheet as of December 31, 2013 was derived from the Company’s audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States. There have been no changes to the Company’s significant accounting policies since December 31, 2013. The unaudited financial statements reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations for the interim periods presented. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other future annual or interim period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the Company’s audited financial statements included in the Company’s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), with the Securities and Exchange Commission (the “SEC”) on July 16, 2014 (the “Prospectus”).
New Accounting Pronouncements	'
	New Accounting Pronouncements
	From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, which is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. This ASU provides guidance to an organization’s management, with principles and definitions that are intended to reduce diversity in the timing and content of disclosures that are commonly provided by organizations today in the financial statement footnotes. The amendments are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016, and early adoption is permitted. The Company is currently in the process of evaluating the impact this new guidance will have.
	In May 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-9, Revenue from Contracts with Customers. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. ASU 2014-9 provides companies with two implementation methods. Companies can choose to apply the standard retrospectively to each prior reporting period presented (full retrospective application) or retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period, and early application is not permitted. The Company is currently in the process of evaluating the impact this new guidance will have.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Summary of Net Inventories	'
	The following table provides details of the Company’s net inventories (amounts in thousands):
		As of September 30,		As of December 31,
		2014		2013
	Raw materials	$	1,597	$	1,846
	Work in process	—		—
	Finished goods	3,297		2,033
		$	4,894	$	3,879

Property_and_Equipment_Tables

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2014
Property, Plant and Equipment [Abstract]	'
Schedule of Property and Equipment	'
	The following table provides details of the Company’s property and equipment (amounts in thousands):
		As of September 30,			As of December 31,
		2014			2013
	Atlas instruments	$	10,160		$	10,330
	Manufacturing equipment	2,801			2,801
	Laboratory equipment	2,967			2,923
	Computer and office equipment	1,435			1,388
	Leasehold improvements	1,318			1,272
	Software	1,113			1,106
	Total property and equipment	$	19,794		$	19,820
	Less: Accumulated depreciation	(7,106		)	(5,310		)
	Total	$	12,688		$	14,510
Schedule of Expenses for Depreciation of Property and Equipment	'
	Expenses for depreciation of property and equipment were incurred as follows (amounts in thousands):
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2014			2013			2014		2013
	Depreciation expense	$	623		$	582		$	1,867	$	1,677

Accrued_Expenses_Tables

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2014
Payables and Accruals [Abstract]	'
Summary of Accrued Expenses	'
	The following table provides details of the Company’s accrued expenses (amounts in thousands):
		As of September 30,		As of December 31,
		2014		2013
	Employee related	$	1,145	$	888
	Professional services	740		1,328
	Other	435		165
	Total accrued expenses	$	2,320	$	2,381

Deferred_Payments_Tables

Deferred Payments (Tables)	9 Months Ended
	Sep. 30, 2014
Other Liabilities Disclosure [Abstract]	'
Summary of Amounts Deferred under Supply Agreement	'
	The following table summarizes the amounts deferred under this agreement (amounts in thousands):
		As of September 30,			As of December 31,
		2014			2013
	Current
	Deferred payments, gross	$	1,002		$	759
	Imputed interest	(393		)	(420		)
	Deferred payments, net	$	609		$	339
	Long-term
	Deferred payments, gross	$	3,776		$	4,053
	Imputed interest	(557		)	(848		)
	Deferred payments, net	$	3,219		$	3,205

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Cash Held in Money Market Deposit Accounts and its Convertible Preferred Stock Warrants	'
	The following table summarizes the fair value information for the Company’s cash held in money market deposit accounts and its Convertible Preferred Stock Warrants at September 30, 2014 and December 31, 2013 (amounts in thousands):
					Fair value measurements using:
		Carrying			Quoted Prices in			Significant Other	Significant
		Value			Active Markets			Observable Inputs	Unobservable
					(Level 1)			(Level 2)	Inputs (Level 3)
	As of September 30, 2014
	Financial Assets:
	Money market deposit accounts	$	62,538		$	62,538		—	—
	As of December 31, 2013
	Financial Assets:
	Money market deposit accounts	$	25,470		$	25,470		—	—
	Financial Liabilities:
	Convertible Preferred Stock Warrants	$	212		—			—	$	212
Summary of the Changes in the Convertible Preferred Stock Warrant Liability	'
	The table below provides a summary of the changes in the Convertible preferred stock warrant liability during the nine months ended September 30, 2014 and the nine months ended September 30, 2013 (amounts in thousands):
		For the Nine Months Ended September 30,
		2014			2013
	Balance at beginning of period	$	212		$	100
	Issuance of Series A Warrants	—			6,674
	Increase in Series E warrant shares	135			—
	Change in fair value of warrants(1)	1,017			2,630
	Settlement of Series A Warrants	—			(9,240		)
	Reclassification to equity(2)	(1,364		)	—
	Balance at end of period	$	—		$	164
	-1	Includes $666,000 of prior period fair value adjustments as discussed in Note 2 above.
	-2	The warrants were re-measured to fair value and reclassified to additional paid-in capital upon the initial public offering.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Recognized Stock Compensation Expense	'
	The Company recognized stock compensation expense as follows (amounts in thousands):
		For the Three Months Ended September 30,					For the Nine Months Ended September 30,
		2014			2013		2014		2013
	Stock options	$	41		$	56	$	174	$	170
	Restricted stock	$	200		$	120	$	591	$	360
Ranges of Assumptions were Utilized for Stock Options Granted	'
	The following ranges of assumptions were utilized for stock options granted:
			For the Nine Months Ended September 30,
			2014	2013
	Expected life in years		5.9-6.0	5.7-6.0
	Interest rate		2.01%-2.04%	0.99%-1.94%
	Volatility		60%	70%
	Dividend yield		—	—

Net_Loss_Per_Share_Tables

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Basic and Diluted Net Loss per Share Applicable to Common Stockholders	'
	The tables in this footnote are retroactively adjusted to show the results as if only the new class of Common Stock was outstanding for the entirety of each of the respective periods.
		For the Three Months Ended September 30,							For the Nine Months Ended September 30,
		2014				2013			2014			2013
	Net loss applicable to common shareholders (thousands)	$	(9,083	)		$	(9,449	)	$	(24,799	)	$	(25,105	)
	Deemed dividend (thousands)	—				—			—			184
	Net loss applicable to common shareholders for computing loss per share (thousands)	$	(9,083	)		$	(9,449	)	$	(24,799	)	$	(24,921	)
	Basic and diluted weighted average common shares outstanding	14,153,715				555,910			5,188,516			488,190
	Basic and diluted loss per share	$	(0.64	)		$	(17.00	)	$	(4.78	)	$	(51.05	)
Calculation of Weighted Average Shares Outstanding , Event of Not Incurring Loss	'
	Had the Company not incurred a loss, the dilutive effect of the unvested restricted stock awards on basic weighted average common shares outstanding and the dilutive effect of potential Common Stock shares issuable for Convertible Preferred Stock, stock options and warrants on the weighted-average number of Common Stock shares outstanding would have been as follows:
		For the Three Months Ended September 30,						For the Nine Months Ended September 30,
		2014			2013			2014		2013
	Basic weighted average shares outstanding	14,153,715			555,910			5,188,516		488,190
	Dilutive effect of unvested restricted stock	301,846			47,278			262,861		21,724
	Basic weighted average shares outstanding had the Company not incurred a loss	14,455,561			603,188			5,451,377		509,914
	Dilutive effect of Convertible Preferred Stock	1,939,212			8,972,373			7,642,775		8,198,836
	Dilutive effect of warrants	208			—			69		—
	Dilutive effect of stock options	339,272			192,005			363,792		96,197
	Diluted weighted average shares outstanding had the Company not incurred a loss	16,734,253			9,767,566			13,458,013		8,804,947

Business_Overview_Narrative_De

Business Overview - Narrative (Details) (USD $)	9 Months Ended		0 Months Ended		9 Months Ended		0 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Jul. 22, 2014	Jul. 22, 2014	Sep. 30, 2014	Jul. 22, 2014	Jul. 22, 2014
			IPO [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Class A and Class B [Member]
				IPO [Member]	IPO [Member]	IPO [Member]
Subsidiary, Sale of Stock [Line Items]	'	'	'	'	'	'	'
Issuance of common stock from initial public offering, net of underwriters’ discounts and issuance costs (in shares)	'	'	'	5,000,000	5,000,000	'	'
IPO, price per share (in USD per share)	'	'	'	'	'	$12	'
Proceeds from issuance of common stock, net of issuance costs	$53,585	$0	$53,200	'	'	'	'
Common stock, conversion basis	'	'	'	'	'	'	'1:1

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Narrative (Details) (USD $)	0 Months Ended			3 Months Ended	9 Months Ended
In Thousands, unless otherwise specified	Jul. 03, 2014	Jul. 03, 2014	Jul. 03, 2014	Mar. 31, 2014	Sep. 30, 2014
	Convertible Preferred Stock [Member]	Series B, Series C and Series E Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Fair Value of Warrants [Member]	Fair Value of Warrants [Member]
Summary Of Significant Accounting Policies [Line Items]	'	'	'	'	'
Fair value of warrants	'	'	'	$435	'
Interest expense	'	'	'	26	'
Other expenses	'	'	'	77	'
Reduction of notes payable	'	'	'	77	'
Increase in deferred financing costs	'	'	'	'	$77
Reverse stock split of common stock	'11.04:1 reverse stock split	'	'	'	'
Reverse stock split, conversion ratio	11.04	0.0906	0.0937	'	'

Cash_and_Cash_Equivalents_Narr

Cash and Cash Equivalents - Narrative (Details) (Cash and Cash Equivalents [Member], Credit Concentration Risk [Member])	9 Months Ended
	Sep. 30, 2014
	financial_institution
Cash and Cash Equivalents [Member] | Credit Concentration Risk [Member]	'
Concentration Risk [Line Items]	'
Number of financial institutions	1

Inventories_Summary_of_Net_Inv

Inventories - Summary of Net Inventories (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$1,597	$1,846
Work in process	0	0
Finished goods	3,297	2,033
Inventory, net	$4,894	$3,879

Property_and_Equipment_Schedul

Property and Equipment - Schedule of Property and Equipment (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$19,794	$19,820
Less: Accumulated depreciation	-7,106	-5,310
Property and Equipment, Net	12,688	14,510
Atlas Instrument [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	10,160	10,330
Manufacturing Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	2,801	2,801
Laboratory Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	2,967	2,923
Computers and Office Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	1,435	1,388
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	1,318	1,272
Software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment, Gross	$1,113	$1,106

Property_and_Equipment_Narrati

Property and Equipment - Narrative (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Cost of equipment on lease or held for lease, net of accumulated depreciation	$12,688	$14,510
Accumulated depreciation	7,106	5,310
Atlas Instrument [Member] | Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Cost of equipment on lease or held for lease, net of accumulated depreciation	9,100	9,800
Accumulated depreciation	$1,100	$500

Property_and_Equipment_Schedul1

Property and Equipment - Schedule of Expenses for Depreciation of Property and Equipment (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Property, Plant and Equipment [Abstract]	'	'	'	'
Depreciation expense	$623	$582	$1,867	$1,677

Intangible_Assets_Narrative_De

Intangible Assets - Narrative (Details) (USD $)	0 Months Ended	1 Months Ended		0 Months Ended		1 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Jul. 22, 2014	Jul. 31, 2014	Jun. 30, 2014	Jan. 01, 2020	Jan. 01, 2018	Jul. 31, 2014	Sep. 30, 2014
	Technology-Based Intangible Assets [Member]	Gen Probe [Member]	Gen Probe [Member]	Gen Probe [Member]	Gen Probe [Member]	Royalty Reduction [Member]	Royalty Reduction [Member]
				Scenario, Forecast [Member]	Scenario, Forecast [Member]	Common Stock [Member]	Common Stock [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'
Option agreement period	'	'	'2 years	'	'	'	'
License agreement option payment	'	'	$2.50	'	'	'	'
Issuance of common stock for royalty reduction (in shares)	'	'	'	'	'	865,063	865,063
Share price (in USD per share)	'	$10.51	'	'	'	'	'
Cash payment for royalties	'	8	'	5	5	'	'
Finite-lived Intangible Assets Acquired	$26.60	'	'	'	'	'	'

Accrued_Expenses_Summary_of_Ac

Accrued Expenses - Summary of Accrued Expenses (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Employee related	$1,145	$888
Professional services	740	1,328
Other	435	165
Total accrued expenses	$2,320	$2,381

Accrued_Expenses_Narrative_Det

Accrued Expenses - Narrative (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'
Issuance costs related to IPO	$526

Deferred_Payments_Narrative_De

Deferred Payments - Narrative (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Jul. 31, 2014

31-May-11

31-May-11

Jan. 01, 2020

Jan. 01, 2018

Jan. 01, 2020

Jan. 01, 2018

Sep. 30, 2014

Sep. 30, 2014

Minimum [Member]

Maximum [Member]

Gen Probe [Member]

Atlas Instrument [Member]

Atlas Instrument [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Gen Probe [Member]

Gen Probe [Member]

January 1, 2020 [Member]

January 1, 2018 [Member]

Gen Probe [Member]

Gen Probe [Member]

Gen Probe [Member]

Gen Probe [Member]

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Gen Probe [Member]

Gen Probe [Member]

Maximum [Member]

Other Liabilities [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Deferred purchase price, percentage

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

Deferred payment period

'

'

'

'

'

'

'

'54 months

'

'

'

'

'

'

'

Debt instrument effective percentage

'

'

'

'

9.90%

11.20%

'

'

'

'

'

'

'

'

'

Non-cash interest expense related to the deferred payments

$104,000

$102,000

$318,000

$266,000

'

'

'

'

'

'

'

'

'

'

'

Royalty payment

'

'

'

'

'

'

$8,000,000

'

'

$5,000,000

$5,000,000

$5,000,000

$5,000,000

'

'

Royalty payment, present value interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

9.00%

7.60%

Deferred_Payments_Summary_of_A

Deferred Payments - Summary of Amounts Deferred under Supply Agreement (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current	'	'
Deferred payments, gross	$1,002	$759
Imputed interest	-393	-420
Deferred payments, net	609	339
Long-term	'	'
Deferred payments, gross	3,776	4,053
Imputed interest	-557	-848
Deferred payments, net	$3,219	$3,205

Notes_Payable_Narrative_Detail

Notes Payable - Narrative (Details) (USD $)

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

10 Months Ended

Nov. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Nov. 30, 2013

Nov. 30, 2013

Nov. 30, 2013

Sep. 30, 2014

Nov. 30, 2013

Mar. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

tranche

Convertible Preferred Stock Series E [Member]

Comerica Loan [Member]

Comerica Loan [Member]

Comerica Loan [Member]

Comerica Loan [Member]

TriplePoint Loan [Member]

TriplePoint Loan [Member]

TriplePoint Loan [Member]

TriplePoint Loan [Member]

TriplePoint Loan [Member]

Comerica and TriplePoint [Member]

Minimum [Member]

Common Stock [Member]

Common Stock [Member]

Debt Instrument, Subjective Change Clause [Member]

SecurityLoan

First Tranche [Member]

London Interbank Offered Rate (LIBOR) [Member]

Second Tranche [Member]

Second Tranche [Member]

Third Tranche [Member]

Third Tranche [Member]

TriplePoint Loan [Member]

Comerica and TriplePoint [Member]

Convertible Preferred Stock Series E [Member]

Second Tranche [Member]

Line of Credit Facility [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of loan and security agreements

2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity

$15,000,000

'

'

'

$5,000,000

'

'

'

$10,000,000

$5,000,000

'

$5,000,000

'

'

'

'

'

Number of tranches

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Maximum borrowing capacity per tranches

5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Minimum interest rate

'

'

'

'

'

'

2.50%

'

'

'

'

'

'

'

'

'

'

Additional minimum interest rate

'

'

'

'

'

'

3.15%

'

'

'

'

'

'

'

'

'

'

Interest rate at period end

'

'

'

6.40%

'

'

'

'

'

9.50%

'

'

'

'

'

'

'

Maturity period

'

'

'

'42 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest only period

'

'

'

'18 months

'

'

'

'12 months

'

'

'

'

'

'

'

'

'

Accrued interest and equal principal payments periods

'

'

'

'23 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Amortization period

'

'

'

'30 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Balloon payment period

'

'

'

'24 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit outstanding

'

'

'

'

'

5,000,000

'

'

'

5,000,000

'

'

'

'

'

'

'

Revenue generated

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

'

'

'

Line of credit maturity term

'

'

'

'

'

'

'

'36 months

'

'

'

'

'

'

'

'

'

Number of shares for warrants exercisable (in shares)

'

'

352,941

'

'

'

'

'

'

'

'

'

'

'

31,968

14,209

'

Warrants outstanding share exercise price (in USD per share)

'

$11.56

$1.28

'

'

'

'

'

'

'

'

'

'

'

$14.08

$14.08

'

Net of expenses paid to Comerica

'

'

'

4,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issuance costs

'

'

'

76,000

'

'

'

153,000

'

'

'

'

'

'

'

'

'

Additional shares for warrants exercisable (in shares)

'

'

'

'

'

'

'

'

'

'

156,863

'

'

'

'

'

'

Warrant liability

'

'

'

'

'

'

'

'

'

135,000

'

'

'

'

'

'

'

Current notes payable

'

'

'

'

'

'

'

'

'

'

'

'

$1,800,000

'

'

'

$8,200,000

Commitments_and_Contingencies_

Commitments and Contingencies - Narrative (Details) (Gen Probe [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Gen Probe [Member]	'
Commitment And Contingencies [Line Items]	'
Additional milestone payments	$6

Fair_Value_Measurements_Fair_V

Fair Value Measurements - Fair Value of Cash Held in Money Market Deposit Accounts and its Convertible Preferred Stock Warrants (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	$62,538	$25,470
Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	'	212
Quoted Prices in Active Markets (Level 1) [Member] | Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	62,538	25,470
Quoted Prices in Active Markets (Level 1) [Member] | Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	'	0
Significant Other Observable Inputs (Level 2) [Member] | Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	0	0
Significant Other Observable Inputs (Level 2) [Member] | Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	'	0
Significant Unobservable Inputs (Level 3) [Member] | Money Market Deposit Accounts [Member]	'	'
Financial Assets:	'	'
Money market deposit accounts	0	0
Significant Unobservable Inputs (Level 3) [Member] | Convertible Preferred Stock Warrants [Member]	'	'
Financial Liabilities:	'	'
Convertible Preferred Stock Warrants	'	$212

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of the Changes in the Convertible Preferred Stock Warrant Liability (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'		'
Balance at beginning of period	$212		$100
Change in fair value of warrants	1,017	[1]	2,630	[1]
Reclassification to equity	-1,364	[2]	0	[2]
Balance at end of period	0		164
Prior Period Adjustment [Member]	'		'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'		'
Fair value of warrants	666		'
Series A Warrants [Member]	'		'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'		'
Issuance of Series A Warrants	0		6,674
Settlement of Series A Warrants	0		-9,240
Series E Warrants [Member]	'		'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'		'
Increase in Series E warrant shares	$135		$0
[1]	Includes $666,000 of prior period fair value adjustments as discussed in Note 2 above.
[2]	The warrants were re-measured to fair value and reclassified to additional paid-in capital upon the initial public offering.

Convertible_Preferred_Stock_an1

Convertible Preferred Stock and Stockholders' Equity (Deficit) - Narrative (Details) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	Jul. 22, 2014	Sep. 30, 2014	Dec. 31, 2013
Temporary Equity [Line Items]	'	'	'
Series A convertible preferred stock, shares outstanding (in shares)	'	0	'
Lock-up period	'	'180 days	'
Percentage of registrable securities	'	51.00%	'
Total stock, shares authorized (in shares)	'	520,000,000	'
Common stock, shares authorized (in shares)	'	500,000,000	'
Common stock, par or stated value per share (in USD per share)	'	0.001	0.001
Preferred stock, shares authorized (in shares)	'	20,000,000	'
Preferred stock, par or stated value per share (in USD per share)	'	0.001	'
Common Stock [Member]	'	'	'
Temporary Equity [Line Items]	'	'	'
Conversion of convertible preferred stock into Common Stock (in shares)	10,494,557	10,494,557	53,688

StockBased_Compensation_Narrat

Stock-Based Compensation - Narrative (Details) (USD $)	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Period between share increases	'10 years	'
Percent of increase	0.03	'
Maximum contractual term of restricted stock granted	'10 years	'
Contractual term of restricted stock vested	'4 years	'
Dividend yield	0.00%	0.00%
2009 Equity Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock options granted under 2009 plan (in shares)	4,000	105,000
Stock options granted, value	18	104
2009 Equity Incentive Plan [Member] | Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock options and restricted shares granted (in shares)	2,028,850	'
2014 Equity Incentive Plan [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0	'
Restricted stock granted (in shares)	0	'
2014 Equity Incentive Plan [Member] | Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Stock options and restricted shares granted (in shares)	1,086,956	'

StockBased_Compensation_Schedu

Stock-Based Compensation - Schedule of Recognized Stock Compensation Expense (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'
Stock options	$41	$56	$174	$170
Restricted stock	$200	$120	$591	$360

StockBased_Compensation_Ranges

Stock-Based Compensation - Ranges of Assumptions were Utilized for Stock Options Granted (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Volatility	60.00%	70.00%
Dividend yield	0.00%	0.00%
Minimum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life in years	'5 years 10 months 24 days	'5 years 8 months 12 days
Interest rate	2.01%	0.99%
Maximum [Member]	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Expected life in years	'6 years	'6 years
Interest rate	2.04%	1.94%

Warrants_Narrative_Details

Warrants - Narrative (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Mar. 31, 2014
In Thousands, except Share data, unless otherwise specified		Comerica Loan [Member]	TriplePoint Loan [Member]	Series B Warrants [Member]	Series E Warrants [Member]	Series E Warrants [Member]
						TriplePoint Loan [Member]
						Second Tranche [Member]
Class of Warrant or Right [Line Items]	'	'	'	'	'	'
Warrants outstanding to purchase shares (in shares)	270,813	'	'	2,480,000	352,941	'
Warrants outstanding share exercise price (in USD per share)	$11.56	'	'	$1	$1.28	'
Warrants conversion ratio	'	'	'	0.0906	0.0906	'
Warrants issued as payments	'	$28	$55	'	'	'
Debt issuance costs	'	'	153	'	'	'
Additional issues shares (in shares)	'	'	'	'	'	156,863
Additional issues shares value	'	'	'	'	'	$135

Net_Loss_Per_Share_Schedule_of

Net Loss Per Share - Schedule of Basic and Diluted Net Loss per Share Applicable to Common Stockholders (Details) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Earnings Per Share [Abstract]	'	'	'	'	'
Net loss applicable to common shareholders (thousands)	($9,083)	($9,449)	($24,799)	($24,921)	'
Deemed dividend (thousands)	0	0	0	184	'
Net loss applicable to common shareholders for computing loss per share (thousands)	($9,083)	($9,449)	($24,799)	($25,105)	($29,578)
Basic and diluted weighted average common shares outstanding (in shares)	14,153,715	555,910	5,188,516	488,190	'
Basic and diluted loss per share (in USD per share)	($0.64)	($17)	($4.78)	($51.05)	'

Net_Loss_Per_Share_Calculation

Net Loss Per Share - Calculation of Weighted Average Shares Outstanding , Event of Not Incurring Loss (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Basic weighted average shares outstanding (in shares)	14,153,715	555,910	5,188,516	488,190
Dilutive effect of unvested restricted stock (in shares)	301,846	47,278	262,861	21,724
Basic weighted average shares outstanding had the Company not incurred a loss (in shares)	14,455,561	603,188	5,451,377	509,914
Dilutive effect of Convertible Preferred Stock (in shares)	1,939,212	8,972,373	7,642,775	8,198,836
Dilutive effect of warrants (in shares)	208	0	69	0
Dilutive effect of stock options (in shares)	339,272	192,005	363,792	96,197
Diluted weighted average shares outstanding had the Company not incurred a loss (in shares)	16,734,253	9,767,566	13,458,013	8,804,947

Segment_Information_Narrative_

Segment Information - Narrative (Details) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
	Segment	Customer
Segment Reporting Information [Line Items]	'	'
Number of Reportable Segments	1	'
Number of customers accounted for more than 10% of revenues	'	2
Customer One [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	1,100,000	504,000
Customer Two [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	648,000	457,000
Customer Three [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	631,000	'
Customer Four [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Revenues of major customer	411,000	'
Revenue [Member]	'	'
Segment Reporting Information [Line Items]	'	'
Number of customers accounted for more than 10% of revenues	4	2
Concentration risk percentage	10.00%	10.00%